🔎 Trials Near Me

Home › Kanser (lahat ng uri) › Ohio › Akron

Pag-aaral pangklinika para sa Kanser (lahat ng uri) sa Akron, OH

14 pag-aaral para sa Kanser (lahat ng uri) ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Akron (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Nagre-recruitPhase 3
  • Aultman Health Foundation, Canton · 21 mi ang layo
Edad 18 pataas · Kababaihan · Na-update Set 29, 2026 · NCT05256225

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

Nagre-recruitPhase 3
  • Investigative Site, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06881992

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Nagre-recruitPhase 1/2
  • GSK Investigational Site, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT07213609

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Nagre-recruitPhase 3
  • Gabrail Cancer & Research Center, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06072612

Project: Every Child for Younger Patients With Cancer

Nagre-recruitObservasyonal na pag-aaral
  • Children's Hospital Medical Center of Akron, Akron
Hanggang edad 25 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT02402244

International Rare Brain Tumor Registry

Nagre-recruitObservasyonal na pag-aaral
  • Akron Children's Hospital, Akron
Hanggang edad 45 · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05697874

Molecular Genetics Studies of Cancer Patients and Their Relatives

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Aultman Health Foundation, Canton · 21 mi ang layo
Lahat ng edad · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT04185935

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Nagre-recruitPhase 2
  • Gabrail Cancer and Research Center, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06463665

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Nagre-recruitObservasyonal na pag-aaral
  • Aultman Medical Group, Canton · 21 mi ang layo
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Peb 24, 2026 · NCT06207032

GEMINI-NSCLC: NSCLC Biomarker Study

Nagre-recruitObservasyonal na pag-aaral
  • Aultman Hospital, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT05236114

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Nagre-recruitPhase 1
  • Gabrail Cancer & Research Center, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 17, 2025 · NCT05856981

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Nagre-recruitPhase 1/2
  • Gabrail Cancer Center Research, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 24, 2025 · NCT06228326

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Nagre-recruitPhase 1/2
  • Gabrail Cancer Center Research, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update May 18, 2025 · NCT05970497

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

Nagre-recruitObservasyonal na pag-aaral
  • Aultman Hospital, Canton · 21 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2025 · NCT05234177

Pag-aaral para sa Kanser (lahat ng uri) sa ibang lungsod

Iba pang pag-aaral sa Akron

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.